Welcome to our dedicated page for Abpro Holdings news (Ticker: ABP), a resource for investors and traders seeking the latest updates and insights on Abpro Holdings stock.
Abpro Holdings reports developments in antibody therapeutics for solid tumors, with recurring updates centered on ABP-102/CT-P72, its HER2 x CD3 T-cell engager co-developed with Celltrion. Company news includes FDA IND activity, oncology conference presentations, preclinical data for HER2-positive cancers, and progress across antibody-engineering platforms including DiversImmune® and MultiMab™.
Abpro updates also cover public-company actions tied to its Nasdaq listing, capital structure, reverse stock split, cost optimization, financing resources, and broader pipeline positioning in oncology and retinal disease indications.
Summary not available.